CRG-022 is under clinical development by CARGO Therapeutics and currently in Phase I for Marginal Zone B-cell Lymphoma. According to GlobalData, Phase I drugs for Marginal Zone B-cell Lymphoma have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CRG-022’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CRG-022 overview
CRG-022 is under development for the treatment of pediatric, young and adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL), refractory or relapsed (r/r) Philadelphia chromosome positive acute lymphoblastic leukemia (Ph positive ALL), diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma, follicular lymphoma, marginal zone B-cell lymphoma and chronic lymphocytic leukemia (CLL). It is a second generation m971 mAb-derived chimeric antigen receptors (CARs) T-cells transduced with lentivirus targeting CD22. It is administered through intravenous route as an infusion. The therapeutic candidate is developed based on the chimeric antigen receptor (CAR) technology.
CARGO Therapeutics overview
CARGO Therapeutics formerly Syncopation Life Sciences, discovers and develops adoptive cell therapies for the treatment of cancer. The company utilizes its proprietary Syncopation insights and platform, to advance primary mechanisms of resistance in chimeric antigen receptor t-cell (CAR-T) therapies; and develops pipeline programs targeting cancer. CARGO Therapeutics with new engineering technologies is developing the next generation of adoptive cell therapies. The company funding partners include Samsara Biocaptial, Emerson Collective and Red Tree Venture Capital. CARGO Therapeutics is headquartered in San Mateo, California, the US.
For a complete picture of CRG-022’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
